GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Carl R. who wrote (2002)	1/10/2000 10:35:00 AM
From: out_of_the_loop	Read Replies (1) of 5582

Tremacamra basically proves the blockade or decoy against ICAM blocks the cycle of infection of rhinoviruses. It will, according to the company, never be produced, though. It is a bioengineered molecule and has been discussed on this thread before. I am off work today so I do not have the other references, so try this government sheet niaid.nih.gov Basically, they are age dependent so the percentages will vary among pediatric, adolescent and adult groups. The percentage of rhinovirus-caused colds varies from 30-65%, depending on who and what you read so I am not alarmed by the percentages in that reference. In any case, you get the idea of what viruses are the "players". Zicam will not prevent the cycle of infection/autoinfection if the ICAM is not the receptor mediating the cycle. It may help in the symptoms somewhat, but that has not been studied yet - I am stating that on the basis of people reporting their allergy symptoms being helped (being studdied now) and some of the mechanisms of inflammation may be affected by Zicam.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next